Plus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improvement on …
Merck’s ADC sac-TMT gets its first global Phase 3 win ahead of schedule
An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the patent cliff for its best-selling …
The Supreme Court won’t take up drugmakers’ IRA cases
The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca, Johnson & …
The Boring Stuff is Dangerous Now
AI agents capable of discovering and exploiting obscure vulnerabilities are emerging alongside developers producing vast amounts of potentially flawed AI-generated code, forcing defenders to adapt accordingly.
Novartis reveals more data behind Pluvicto expansion bid
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
Boulevard of Broken Dreams: 2 Decades of Cyber Fails
From the MGM and Caesars fiasco and MOVEit’s patch nightmare to epic business blunders and the jaded reality of living in a post-breach world, Dark Reading looks back at the mistakes, miscalculations, systemic failures, and cringeworthy moments that still have us shaking our heads.
WHO says Ebola outbreak in Congo is a “public emergency”
As deaths from an Ebola virus outbreak in DRC and Uganda rise above 80, the FDA has declared it a public health emergency of international concern.
Regeneron’s Phase 3 skin cancer miss adds to mounting failures in LAG-3
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent clinical setbacks for candidates targeting the LAG-3 …
AZ gets first okay for new hypertension drug baxdrostat
AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.
FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood …
Another LAG-3 setback as Regeneron drug fails phase 3 trial
Regeneron’s LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.
Eli Lilly teams up with Caitlin Clark to bounce sports courts into Indianapolis neighborhoods
Eli Lilly has partnered with basketball star Caitlin Clark’s foundation to open three multisport community courts across Indianapolis.